Chimigen Biomedical (Chengdu) Co., Ltd. (Chimigen), a biotech company dedicated to the development of innovative therapeutic vaccines, has closed an oversubscribed Pre-A funding round totaling nearly 170 million RMB.
2025-07-22
Chimigen Biomedical (Chengdu) Co., Ltd. (Chimigen) recently announced that the Investigational New Drug (IND) application for SN2001, a therapeutic vaccine for chronic hepatitis B, has been approved by the US FDA. Phase I clinical trials officially commen
2025-07-07
PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider
2024-01-05
On September 12, 2023, Genevoyager (Wuhan) Co., Ltd. (“Genevoyager”) proudly announces the successful completion of its Series A financing round, securing substantial funding to accelerate the expansion of its Gene Therapy Contract Development and Manufac
2023-09-27
US: 3675 Market Street, Suite 200, Philadelphia, PA19104 Tel: +1 (215) 205-6963 | +086 027-65023363
E-mail: hui.wang@genevoyager.com
China: No128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China Tel: 17720522078
E-mail: marketing@genevoyager.com
US: 3675 Market Street, Suite 200, Philadelphia, PA19104 Tel: +1 (215) 205-6963 | +086 027-65023363
E-mail: hui.wang@genevoyager.com
China: No128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China Tel: 17720522078
E-mail: marketing@genevoyager.com
